- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00653380
Bioavailability Study of Doxycycline Monohydrate Capsules and Monodox Under Fasting Conditions
April 1, 2008 updated by: Par Pharmaceutical, Inc.
Randomized, Open-Label, 2-Way Crossover, Comparative Bioavailability Study of Par's and Oclassen's (Monodox) Doxycycline Monohydrate Capsules Administered as 1 x 100 mg Capsule in Healthy Adult Males Under Fasting Conditions
To compare the rate and extent of absorption of doxycycline monohydrate capsules equivalent to 100 mg doxycycline (Par) versus Monodox (Oclassen Pharmaceuticals).
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
To compare the rate and extent of absorption of doxycycline monohydrate capsules equivalent to 100 mg of doxycycline by Par Pharmaceutical, Inc., USA (test) versus Monodox by Oclassen Pharmaceuticals, Inc., USA reference administered as a 1 x 100 mg capsule under fasting conditions.
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Quebec
-
Sainte-Foy, Quebec, Canada, G1V 2K8
- Anapharm, Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 53 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Subjects will be males, non-smokers
- Between 18 and 55 years of age
- Subjects weight will be within 15% of their ideal body weight, based on Table of "Desirable Weight of Adults", Metropolitan Life Insurance Company, 1983
- Subjects should read, sign and date an Informed Consent Form prior to any study procedures
- Subjects must complete all screening procedures within 28 days prior to the administration of the study medication
Exclusion Criteria:
- Clinically significant abnormalities found during medical screening
- Any clinically significant history of ongoing problems or problems known to interfere with the absorption, distribution, metabolism or excretion of drugs of drugs
- Clinically significant illnesses within 4 weeks of the administration of study medication
- Abnormal laboratory tests judged clinically significant
- ECG or vital sign abnormalities (clinically significant)
- History of allergic reactions to heparin
- Any food allergies, intolerances, restrictions, or special diet which in the opinion of the medical subinvestigator, contraindicates the subject's participation in the study
- History of severe allergies or hay fever
- Active asthma or bronchospasm
- Positive urine drug screen at screening
- Positive testing for hepatitis B, hepatitis C or HIV at screening
- Use of investigational drug or participation in an investigational study, within 30 days prior to administration of the study medication
- Recent donation of plasma (500 mL) within 7 days or recent donation or significant loss of whole blood (450 mL) within 56 days prior to the administration of the study medication
- History of significant alcohol abuse within six months of the screening visit or any indication of the regular use of more than two units of alcohol per day
- Recent history of drug abuse or use of illegal drugs: soft drugs (marijuana, pot) use within 3 months of the screening visit and hard drugs (cocaine, PCP, crack) use within 1 year of the screening visit
- Subjects who have taken prescription medication 14 days preceding administration of study medication or over-the-counter products 7 days preceding administration of study medication, except for topical products without systemic absorption
- Subjects who have taken any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to administration of the study medication
- Subjects who have undergone clinically significant surgery within 4 weeks prior to the administration of the study medication
- Any reason which, in the opinion of the medical subinvestigator, would prevent the subject from participating in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A
Subjects received the Par product (Doxycycline Monohydrate) under fasting conditions.
|
Capsules, 100 mg, single-dose
Other Names:
|
Active Comparator: B
Subjects received Oclassen's product (Monodox) under fasting conditions.
|
Capsules, 100 mg, single-dose
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate and extent of absorption
Time Frame: 72 hours
|
72 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Eric Masson, Pharm.D., Anapharm
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 1999
Primary Completion (Actual)
October 1, 1999
Study Completion (Actual)
October 1, 1999
Study Registration Dates
First Submitted
April 1, 2008
First Submitted That Met QC Criteria
April 1, 2008
First Posted (Estimate)
April 4, 2008
Study Record Updates
Last Update Posted (Estimate)
April 4, 2008
Last Update Submitted That Met QC Criteria
April 1, 2008
Last Verified
April 1, 2008
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 99061
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on To Determine Bioequivalence Under Fasting Conditions
-
Par Pharmaceutical, Inc.Novum Pharmaceutical Research ServicesCompletedTo Determine the Bioequivalence Study Under Fasting
-
Par Pharmaceutical, Inc.Algorithme Pharma IncCompletedTo Determine the Bioequivalence Study Under FastingCanada
-
Par Pharmaceutical, Inc.BASi Clinical Research UnitCompletedTo Determine Bioequivalence Under Fasting ConditionsUnited States
-
Par Pharmaceutical, Inc.AAI ClinicCompletedTo Determine Bioequivalence Under Fasting Conditions
-
Par Pharmaceutical, Inc.AnapharmCompletedTo Determine Bioequivalence Under Fasting ConditionsCanada
-
Par Pharmaceutical, Inc.AnapharmCompletedTo Determine Bioequivalence Under Fasting ConditionsCanada
-
Par Pharmaceutical, Inc.AnapharmCompletedTo Determine Bioequivalence Under Fasting ConditionsCanada
-
Par Pharmaceutical, Inc.Phoenix International Life Sciences, Inc.CompletedTo Determine Bioequivalence Under Fasting ConditionsCanada
-
Par Pharmaceutical, Inc.Cetero Research, San AntonioCompletedTo Determine the Bioequivalence Under Fasting ConditionsUnited States
-
Par Pharmaceutical, Inc.SFBC AnapharmCompletedTo Determine Bioequivalence Under Fasting ConditionsCanada
Clinical Trials on Doxycycline Monohydrate
-
Par Pharmaceutical, Inc.AnapharmCompletedTo Determine Bioequivalence Under Fed ConditionsCanada
-
Teva Pharmaceuticals USACompleted
-
Teva Pharmaceuticals USACompleted
-
Thomas GardnerJuvenile Diabetes Research FoundationCompleted
-
PfizerCompleted
-
Medical College of WisconsinNational Heart, Lung, and Blood Institute (NHLBI)CompletedPrimary Systemic AmyloidosisUnited States
-
Par Pharmaceutical, Inc.AnapharmCompletedTo Determine Bioequivalence Under Fasting ConditionsCanada
-
Par Pharmaceutical, Inc.AnapharmCompletedTo Determine Bioequivalence Under Fed ConditionsCanada
-
Thomas GardnerJuvenile Diabetes Research Foundation; Penn State UniversityCompletedDiabetic RetinopathyUnited States
-
Ranbaxy Laboratories LimitedCompletedHealthyUnited States